448 related articles for article (PubMed ID: 30442944)
21. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
[TBL] [Abstract][Full Text] [Related]
22. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.
Schrand B; Berezhnoy A; Brenneman R; Williams A; Levay A; Kong LY; Rao G; Zhou S; Heimberger AB; Gilboa E
Cancer Immunol Res; 2014 Sep; 2(9):867-77. PubMed ID: 24938283
[TBL] [Abstract][Full Text] [Related]
23. Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory.
Park JJ; Anand S; Zhao Y; Matsumura Y; Sakoda Y; Kuramasu A; Strome SE; Chen L; Tamada K
Cancer Immunol Immunother; 2012 Feb; 61(2):203-214. PubMed ID: 21877247
[TBL] [Abstract][Full Text] [Related]
24. Agonist-induced 4-1BB activation prevents the development of Sjӧgren's syndrome-like sialadenitis in non-obese diabetic mice.
Zhou J; You BR; Yu Q
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165605. PubMed ID: 31740402
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.
Quetglas JI; Dubrot J; Bezunartea J; Sanmamed MF; Hervas-Stubbs S; Smerdou C; Melero I
Mol Ther; 2012 Sep; 20(9):1664-75. PubMed ID: 22735380
[TBL] [Abstract][Full Text] [Related]
26. ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
Enell Smith K; Fritzell S; Nilsson A; Barchan K; Rosén A; Schultz L; Varas L; Säll A; Rose N; Håkansson M; von Schantz L; Ellmark P
Cancer Immunol Immunother; 2023 Dec; 72(12):4145-4159. PubMed ID: 37796298
[TBL] [Abstract][Full Text] [Related]
27. Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody.
Ju SA; Park SM; Lee SC; Kwon BS; Kim BS
Mol Cells; 2007 Aug; 24(1):132-8. PubMed ID: 17846508
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
Chester C; Sanmamed MF; Wang J; Melero I
Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
[TBL] [Abstract][Full Text] [Related]
29. Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody.
Yu M; Scherwitzl I; Opp S; Tsirigos A; Meruelo D
J Immunother Cancer; 2019 Jul; 7(1):185. PubMed ID: 31307539
[TBL] [Abstract][Full Text] [Related]
30. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.
Schabowsky RH; Elpek KG; Madireddi S; Sharma RK; Yolcu ES; Bandura-Morgan L; Miller R; MacLeod KJ; Mittler RS; Shirwan H
Vaccine; 2009 Dec; 28(2):512-22. PubMed ID: 19836479
[TBL] [Abstract][Full Text] [Related]
31. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
Wen T; Bukczynski J; Watts TH
J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439
[TBL] [Abstract][Full Text] [Related]
32. Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.
Ho SK; Xu Z; Thakur A; Fox M; Tan SS; DiGiammarino E; Zhou L; Sho M; Cairns B; Zhao V; Xiong M; Samayoa J; Forsyth CM; Powers DB; Chao DT; Hollenbaugh D; Alvarez HM; Akamatsu Y
Mol Cancer Ther; 2020 Apr; 19(4):1040-1051. PubMed ID: 31974274
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells.
Innamarato P; Asby S; Morse J; Mackay A; Hall M; Kidd S; Nagle L; Sarnaik AA; Pilon-Thomas S
J Immunol; 2020 Nov; 205(10):2893-2904. PubMed ID: 33020146
[TBL] [Abstract][Full Text] [Related]
34. Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
Hangiu O; Compte M; Dinesen A; Navarro R; Tapia-Galisteo A; Mandrup OA; Erce-Llamazares A; Lázaro-Gorines R; Nehme-Álvarez D; Domínguez-Alonso C; Harwood SL; Alfonso C; Blanco B; Rubio-Pérez L; Jiménez-Reinoso A; Díez-Alonso L; Blanco FJ; Sanz L; Howard KA; Álvarez-Vallina L
iScience; 2022 Sep; 25(9):104958. PubMed ID: 36072551
[TBL] [Abstract][Full Text] [Related]
35. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.
McNamara JO; Kolonias D; Pastor F; Mittler RS; Chen L; Giangrande PH; Sullenger B; Gilboa E
J Clin Invest; 2008 Jan; 118(1):376-86. PubMed ID: 18060045
[TBL] [Abstract][Full Text] [Related]
36. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis.
Sun Y; Lin X; Chen HM; Wu Q; Subudhi SK; Chen L; Fu YX
J Immunol; 2002 Feb; 168(3):1457-65. PubMed ID: 11801689
[TBL] [Abstract][Full Text] [Related]
37. EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8
Stairiker CJ; Pfister SX; Hendrickson E; Yang W; Xie T; Lee C; Zhang H; Dillon C; Thomas GD; Salek-Ardakani S
Front Immunol; 2021; 12():770080. PubMed ID: 34925340
[TBL] [Abstract][Full Text] [Related]
38. Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization.
Willoughby JE; Kerr JP; Rogel A; Taraban VY; Buchan SL; Johnson PW; Al-Shamkhani A
J Immunol; 2014 Jul; 193(1):244-51. PubMed ID: 24860188
[TBL] [Abstract][Full Text] [Related]
39. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
40. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination.
Tan JT; Whitmire JK; Murali-Krishna K; Ahmed R; Altman JD; Mittler RS; Sette A; Pearson TC; Larsen CP
J Immunol; 2000 Mar; 164(5):2320-5. PubMed ID: 10679066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
